SonoSite hits profitability in 2Q

As sales of SonoSite's flagship compact ultrasound system exceeded 60 percent of worldwide revenue, the company reported "significantly improved results" in the second quarter of 2004 compared with the second quarter of 2003.

Worldwide revenue in the second quarter grew 30 percent to $26.1 million, compared with 20.1 million in the year-ago quarter. For the fist half of 2004, the company's total revenue grew 33 percent to $49.6 million, compared with $37.3 million in the year-ago period.

SonoSite also reported a net loss of $64,000, compared with a net loss of $1.3 million in the second quarter of 2003.

"Our European sales are benefiting from the recent launch of the 2.2 Titan upgrade with its shared service capabilities for both cardiology and radiology imaging," said Kevin Goodwin, president and CEO. "Worldwide sales of our Titan high performance systems continue to strengthen and now account for over 60 percent of worldwide revenue. We are focused in accelerating U.S. sales growth and have taken several steps to establish the foundation for improved long-term growth. Development of our third-generation digital architecture, Gen III, continues on schedule."

Around the web

RBMA President Peter Moffatt discusses some of the biggest obstacles facing the specialty in the new year. 

Deepak Bhatt, MD, director of the Mount Sinai Fuster Heart Hospital and principal investigator of the TRANSFORM trial, explains an emerging technique for cardiac screening: combining coronary CT angiography with artificial intelligence for plaque analysis to create an approach similar to mammography.

A total of 16 cardiology practices from 12 states settled with the DOJ to resolve allegations they overbilled Medicare for imaging agents used to diagnose cardiovascular disease.